Initial Treatment for Inflammatory Arthritis

First-Line Treatment Algorithm

The European League Against Rheumatism recommends referring patients with joint swelling, pain, or stiffness to a rheumatologist within 6 weeks of symptom onset 1, 2
The American College of Rheumatology suggests performing clinical examination to detect synovitis, which may be confirmed by ultrasonography if needed 1
Assess risk factors for persistent/erosive disease including the number of swollen and tender joints, elevated ESR or CRP, presence of rheumatoid factor and anti-CCP antibodies, and radiographic erosions 1, 2
For patients at risk of persistent inflammatory arthritis, start methotrexate at 10-15 mg/week, increasing to 15-25 mg/week as tolerated 3, 4, 5
Consider short-term systemic glucocorticoids (prednisone) at low doses for temporary (<6 months) symptom relief 1, 6

The American College of Rheumatology recommends using NSAIDs at minimum effective dose for shortest time possible after evaluating GI, renal, and cardiovascular risks 1, 2, 6
Temporary systemic glucocorticoids may be used to bridge until DMARDs take effect 1, 6

Assess disease activity every 1-3 months until treatment target is reached 1, 5
Monitor using tender and swollen joint counts, patient and physician global assessments, ESR and CRP, and composite measures like SDAI or CDAI 1, 3, 4, 5
Target should be remission (SDAI ≤3.3, CDAI ≤2.8) or at least low disease activity (SDAI ≤11, CDAI ≤10) 3, 4, 5

For patients with moderate disease activity (SDAI >11 to ≤26 or CDAI >10 to ≤22) after 3-6 months on MTX, add sulfasalazine and hydroxychloroquine for triple DMARD therapy 3, 4, 5
For patients with high disease activity (SDAI >26 or CDAI >22) at 3 months despite MTX, add a biologic agent (TNF inhibitor or abatacept) 3, 4, 5

Non-pharmacological interventions should be incorporated, including dynamic exercises and occupational therapy, patient education about disease management, and programs for coping with pain and maintaining work ability 1, 2, 6

Delaying DMARD therapy beyond 3 months of symptom onset can lead to irreversible joint damage 1
Using suboptimal doses of MTX (optimal dose range is 15-25 mg/week) 3, 4
Failing to monitor disease activity regularly and adjust therapy accordingly 1, 5
Not considering triple DMARD therapy (MTX + sulfasalazine + hydroxychloroquine) before biologics in moderate disease 3, 4, 5

Initial treatment with methotrexate (MTX) plus short-term glucocorticoids achieves remission in 40-50% of patients with early rheumatoid arthritis, as recommended by the European League Against Rheumatism (EULAR) 7, 8

Intensive treatment strategies with close monitoring and treat-to-target approaches achieve higher remission rates than conventional care, with a strength of evidence level of I (high quality) according to the American College of Rheumatology (ACR) 7, 9
Combination therapy with conventional DMARDs plus steroids or biological therapy with methotrexate provides superior clinical and radiological outcomes than monotherapy, with a number needed to treat (NNT) of 5, as reported by the EULAR 7, 9

Monitoring disease activity every 1-3 months using tender and swollen joint counts, patient and physician global assessments, ESR, and CRP is recommended by the ACR to adjust therapy accordingly 8, 10
Adding a biologic agent (TNF inhibitor, abatacept, tocilizumab) or JAK inhibitor is recommended for patients with high disease activity or poor prognostic factors, with a strength of evidence level of II (moderate quality) according to the EULAR 8, 11

Early remission is associated with arrest of radiographic progression and better physical function, with a hazard ratio of 0.5, as reported by the EULAR 9

Failing to monitor disease activity regularly (every 1-3 months) and adjust therapy accordingly reduces remission rates, with a relative risk of 1.5, as reported by the ACR 8, 10
Underestimating the importance of glucocorticoids as bridge therapy while waiting for DMARDs to take full effect is a common pitfall, with a strength of evidence level of III (low quality) according to the EULAR 7